Theravance Biopharma reports Q4 2023 GAAP net loss $8.5M; non-GAAP net profit $1.4M; YUPELRI net sales up 9% to $60.6M

Theravance Biopharma, Inc.

2023-FY EPS reported -$1.00 revenue$57,424,000

Q4 YUPELRI net sales recognized by Viatris grew 9% YoY to $60.6M record high; full-year Viatris collaboration revenue up 18% to $57.2M.
GAAP net loss of $8.5M in Q4; achieved non-GAAP net profit of $1.4M, driven by YUPELRI growth and expense management.
Completed $325M capital return program early Jan 2024, reducing shares outstanding by 37%.
YUPELRI hospital volumes grew 46% YoY, exceeding targets; CYPRESS study enrollment on track for H2 2024.
Ampreloxetine granted FDA Orphan Drug Designation; investor event planned for Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theravance Biopharma, Inc. reported full year ended December 31, 2023 results: revenue $57.2 million.

Period: full year ended December 31, 2023
Revenue: $57.2 million
Result: reported results

Exact text from the filing

· Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Theravance Biopharma, Inc. reported Q4 2023 results: net income $8.5 million.

Period: Q4 2023
Net income: $8.5 million
Result: reported results

Exact text from the filing

· GAAP Net Loss of $8.5 million in Q4; Achieved goal of profitability on Non-GAAP basis in Q4, with Non-GAAP Net Profit of $1.4 million 2

View on SEC.gov

Browse all earnings releases →

Theravance Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-027510

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.